<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9177">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05703672</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00146887</org_study_id>
    <nct_id>NCT05703672</nct_id>
  </id_info>
  <brief_title>Switching to E-cigarettes in African-American Smokers</brief_title>
  <official_title>4th Generation E-cigarettes in African American Smokers: Reducing Harm and Quitting Combustible Cigarettes in Dual Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this application are to 1) compare short- and long-term harm reduction and&#xD;
      abuse liability potential of a nicotine salt pod-based electronic cigarettes (EC) in African&#xD;
      American (AA) exclusive EC, dual cig-EC, and exclusive cig users, 2) characterize factors&#xD;
      that predict who switches fully, partially, or not at all, and 3) examine if harm reduction&#xD;
      can be further enhanced by treating dual users with varenicline (VAR) to eliminate cigarette&#xD;
      smoking.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      African American (AA) cigarette smokers (n=500) who are interested in switching to a nicotine&#xD;
      salt-based electronic cigarette (EC) and are not established EC users will receive a 6-week&#xD;
      supply of the EC and assistance with switching. After six weeks, those that are dual users&#xD;
      (n=221) will receive an additional 12 weeks of the EC and be randomized in a 2:1 fashion to&#xD;
      receive 12 weeks of varenicline (VAR) or placebo (PBO) and additional counseling to support a&#xD;
      complete switch. Follow-up for all participants will continue through week 52. The primary&#xD;
      outcome is change in the potent lung carcinogen, NNAL, between exclusive EC, dual cig-EC, and&#xD;
      exclusive cig users at week 6.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2023</start_date>
  <completion_date type="Anticipated">August 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in toxicant exposure as measured by NNAL (4- (methylnitrosamino)-1-(3-pyridyl)-1-butanol) .</measure>
    <time_frame>Week 6</time_frame>
    <description>Reduction in toxicant exposure as measured by NNAL excretion from baseline to week 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Carbon Monoxide (CO) verified 7-day point prevalence abstinence from cigarettes</measure>
    <time_frame>Week 12 post randomization</time_frame>
    <description>CO verified 7-day point prevalence abstinence from cigarettes at week 12 post randomization.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Smoking Reduction</condition>
  <arm_group>
    <arm_group_label>Varenicline and electronic cigarette</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At the end of the 6-week open label phase, dual users of cigarettes and e-cigarettes will receive 1mg varenicline to take twice daily for 12 weeks. They will also receive an additional 12 weeks of the nicotine salt-based pod system e-cigarette.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and electronic cigarette</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>At the end of the 6-week open label phase, dual users of cigarettes and e-cigarettes will receive placebo pills to take twice daily for 12 weeks. They will also receive an additional 12 weeks of the nicotine salt-based pod system e-cigarette.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open label electronic cigarette</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants will receive an initial 6-week supply of the study electronic cigarette.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline Tartrate</intervention_name>
    <description>0.5 mg once daily for days 1-3, 0.5mg twice daily for days 4-7 and 1.0 mg twice daily from day 8 through week 12.</description>
    <arm_group_label>Varenicline and electronic cigarette</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One pill (white) once daily for days 1-3, one pill (white) twice daily for days 4-7 and one pill (blue) twice daily from day 8 through week 12.</description>
    <arm_group_label>Placebo and electronic cigarette</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic cigarette</intervention_name>
    <description>Nicotine salt pod based e-cigarette in 5% nicotine</description>
    <arm_group_label>Open label electronic cigarette</arm_group_label>
    <arm_group_label>Placebo and electronic cigarette</arm_group_label>
    <arm_group_label>Varenicline and electronic cigarette</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  African American&#xD;
&#xD;
          -  â‰¥ 21 years of age&#xD;
&#xD;
          -  Smoke &gt;5 cigarettes per day&#xD;
&#xD;
          -  Smoked cigarettes for &gt; 6 months&#xD;
&#xD;
          -  Verified smoker (CO &gt; 5 ppm)&#xD;
&#xD;
          -  Functioning telephone&#xD;
&#xD;
          -  Interested in switching to EC&#xD;
&#xD;
          -  Willing to take varenicline and complete all study visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Interested in quitting smoking&#xD;
&#xD;
          -  Use of smoking cessation pharmacotherapy in the month prior to enrollment&#xD;
&#xD;
          -  Use of other tobacco products in past 30 days (i.e., cigarillos, cigars, hookah,&#xD;
             smokeless tobacco, pipes)&#xD;
&#xD;
          -  EC use on &gt; 4 of the past 30 days&#xD;
&#xD;
          -  Uncontrolled hypertension: BP &gt; 180 (systolic) or &gt; 105 (diastolic)&#xD;
&#xD;
          -  Heart-related event in the past 30 days&#xD;
&#xD;
          -  Medical contraindications to VAR: unstable cardiac condition (e.g., unstable angina or&#xD;
             AMI) cardiac event, or stroke in the past 4 weeks; renal impairment; history of&#xD;
             clinically significant allergic reactions; history of epilepsy or seizure disorder;&#xD;
             hospitalized for psychiatric issue in past 30 days; active suicidal ideation&#xD;
&#xD;
          -  Pregnant, contemplating getting pregnant, or breastfeeding&#xD;
&#xD;
          -  Plans to move from Kansas City metro area during the treatment and follow-up phase&#xD;
&#xD;
          -  Another household member enrolled in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole Nollen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kanas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tricia Snow, MPH</last_name>
    <phone>816-398-8960</phone>
    <email>psnow@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Swope Health Central</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>January 19, 2023</study_first_submitted>
  <study_first_submitted_qc>January 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2023</study_first_posted>
  <last_update_submitted>May 8, 2023</last_update_submitted>
  <last_update_submitted_qc>May 8, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

